Roche Holding AG

OTCPK:RHHV.F Stock Report

Market Cap: US$323.4b

Roche Holding Valuation

Is RHHV.F undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Future Cash Flow Value

What is the Fair Price of RHHV.F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: RHHV.F ($430) is trading below our estimate of future cash flow value ($1015.08)

Significantly Below Future Cash Flow Value: RHHV.F is trading below future cash flow value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for RHHV.F?

Key metric: As RHHV.F is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for RHHV.F. This is calculated by dividing RHHV.F's market cap by their current earnings.
What is RHHV.F's PE Ratio?
PE Ratio19.7x
EarningsCHF 12.88b
Market CapCHF 254.13b

Price to Earnings Ratio vs Peers

How does RHHV.F's PE Ratio compare to its peers?

The above table shows the PE ratio for RHHV.F vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average18.5x
MRK Merck
15.7x7.94%US$287.3b
JNJ Johnson & Johnson
21.8x2.65%US$585.6b
BMY Bristol-Myers Squibb
17x-0.04%US$122.1b
PFE Pfizer
19.7x-3.73%US$155.2b
RHHV.F Roche Holding
19.7x9.26%US$254.1b

Price-To-Earnings vs Peers: RHHV.F is expensive based on its Price-To-Earnings Ratio (19.7x) compared to the peer average (18.5x).

Historical Price to Earnings Ratio

Historical Price to Earnings Ratio compares a stock's price to its earnings over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Earnings Ratio vs Industry

How does RHHV.F's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?

5 CompaniesPrice / EarningsEstimated GrowthMarket Cap
NDOI Endo
0.3xn/aUS$1.76b
BTMD biote
1.8x-77.82%US$78.54m
OWPC One World Products
0.3xn/aUS$1.25m
KOAN Resonate Blends
0.4xn/aUS$524.88k
RHHV.F 19.7xIndustry Avg. 17.7xNo. of Companies5PE01020304050+
5 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: RHHV.F is expensive based on its Price-To-Earnings Ratio (19.7x) compared to the US Pharmaceuticals industry average (18x).

Price to Earnings Ratio vs Fair Ratio

What is RHHV.F's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

RHHV.F PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio19.7x
Fair PE Ratio31.8x

Price-To-Earnings vs Fair Ratio: RHHV.F is good value based on its Price-To-Earnings Ratio (19.7x) compared to the estimated Fair Price-To-Earnings Ratio (31.8x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst RHHV.F forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$430.00
US$462.51
+7.56%
13.24%US$544.61US$292.67n/a19
Mar ’27US$480.00
US$462.39
-3.67%
13.62%US$556.73US$299.18n/a19
Feb ’27US$443.14
US$454.47
+2.56%
13.60%US$553.69US$297.54n/a20
Jan ’27US$412.92
US$409.44
-0.84%
14.03%US$527.59US$290.30n/a18
Dec ’26US$389.27
US$382.14
-1.83%
15.12%US$519.36US$285.77n/a18
Nov ’26US$324.32
US$372.66
+14.90%
15.77%US$522.13US$287.30n/a18
Oct ’26US$353.22
US$376.19
+6.50%
17.09%US$549.56US$288.58n/a17
Sep ’26US$325.56
US$372.71
+14.48%
16.96%US$546.63US$287.04n/a18
Aug ’26US$316.57
US$369.70
+16.78%
15.93%US$539.24US$283.16n/a19
Jul ’26US$330.82
US$381.93
+15.45%
16.10%US$572.96US$277.65n/a20
Jun ’26US$323.35
US$367.83
+13.76%
16.10%US$551.82US$267.40n/a20
May ’26US$321.52
US$367.76
+14.38%
16.12%US$547.26US$265.19n/a20
Apr ’26US$329.00
US$356.42
+8.33%
14.50%US$506.85US$260.21n/a20
Mar ’26US$329.35
US$344.04
+4.46%
15.54%US$498.19US$255.77US$480.0020
Feb ’26US$313.00
US$335.56
+7.21%
15.74%US$480.94US$252.55US$443.1419
Jan ’26US$280.00
US$337.80
+20.64%
16.62%US$489.96US$256.11US$412.9218
Dec ’25US$287.90
US$343.28
+19.24%
16.89%US$499.74US$249.87US$389.2718
Nov ’25US$312.59
US$351.80
+12.54%
17.04%US$507.26US$254.79US$324.3217
Oct ’25US$312.44
US$356.88
+14.22%
17.32%US$519.96US$259.98US$353.2218
Sep ’25US$336.07
US$349.03
+3.86%
17.07%US$519.47US$259.74US$325.5619
Aug ’25US$322.05
US$327.84
+1.80%
17.11%US$501.32US$250.66US$316.5719
Jul ’25US$276.25
US$308.49
+11.67%
20.43%US$473.95US$232.55US$330.8219
Jun ’25US$248.36
US$307.19
+23.69%
20.54%US$473.74US$232.44US$323.3519
May ’25US$236.00
US$304.45
+29.00%
20.62%US$465.65US$228.47US$321.5218
Apr ’25US$252.41
US$310.97
+23.20%
19.88%US$468.76US$232.17US$329.0018
Mar ’25US$262.50
US$321.47
+22.47%
19.26%US$481.74US$238.60US$329.3518
US$491.18
Fair Value
12.5% undervalued intrinsic discount
19
Number of Analysts

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/03/12 11:27
End of Day Share Price 2026/03/12 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Roche Holding AG is covered by 46 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
John StaszakArgus Research Company
Gerhard SchwarzBaader Helvea Equity Research
Emily FieldBarclays